Objective: The effects of GABA modulating drugs and nicotine, the prototypical nicotinic cholinergic agonist, on attention have been investigated using subcomponents of the P300 event-related potentials (ERP), which index involuntary (P3a) and voluntary attention (P3b). However, investigations into how such pharmacologic effects interact with genetic features in the GABA system remain unclear. This study examined the moderating effects of a single nucleotide polymorphism (rs7557793) in the glutamic acid decarboxylase 67 (GAD1) gene, which is implicated in the conversion of glutamate to GABA, on P300-indices of auditory attentional processing; the influence of nicotine administration was also assessed.
voluntary attentional processing of task-relevant stimuli (Turetsky et al., 2007 ). An earlier (~200 ms) negative ERP, known as the N200 or N2, is believed to reflect pre-attentive automatic detection of stimulus change (indexed by the anteriorly distributed N2a subcomponent) and controlled detection of stimulus change (indexed by the centrally distributed N2b subcomponent; Ritter et al., 1992) .
Many studies have shown that the cholinergic system is implicated in the regulation of attention, memory, and sensory gating through the activation of α7 nicotinic acetylcholine receptors (nAChRs; Buchanan, Freedman, Javitt, Abi-Dargham, & Lieberman, 2007) . The GABAergic system is also known to facilitate cognitive function by inhibiting inappropriate neural activations and thus permitting selective attention to task-relevant signals (Paine, Slipp, & Carlezon, 2011; Rolls, Loh, Deco, & Winterer, 2008; Winterer & Weinberger, 2004) . Nicotine, an α7-nAChR agonist, has been found to improve cognitive domains such as attention and working memory in healthy individuals (Leiser, Bowlby, Comery, & Dunlop, 2009 ). On the other hand, reduced prefrontal GABA levels in healthy individuals have been associated with impaired cognitive functions such as attention and memory (Enomoto, Tse, & Floresco, 2011; Fujiwara, Zheng, Miyamoto, & Hoshino, 2011; Paine et al., 2011; Pehrson, Bondi, Totah, & Moghaddam, 2012; Rolls et al., 2008) .
As such, the cholinergic and GABAergic systems may modulate cognitive function, which can be assessed via P300 and N200 ERPs.
Acute nicotine administration and smoking (1-2 cigarettes) have both been shown to enhance P3b amplitudes, shorten P300 latencies (Houlihan, Pritchard, & Robinson, 1996; Knott, Hooper, LuskMikkelsen, & Kerr, 1995) , and reduce P3a amplitudes in nonsmokers (Knott et al., 2009 (Knott et al., , 2011 . In contrast, chronic smoking (Hedges & Bennett, 2014) and smoking deprivation in smokers have been reported to reduce P300 amplitudes (Evans et al., 2013 .
Interindividual variability in the cognitive enhancing effects of nicotine has also been shown to be baseline-dependent, whereby P3a and P3b amplitudes were enhanced during the automatic processing of novel stimuli in healthy nonsmokers with low (vs. medium or high) baseline P3a/P3b amplitudes (Knott et al., 2014) , suggesting that trait influences on nicotinic neurotransmission may affect attention. Compared with the P300, fewer studies have examined nicotine's effect on the N200. Houlihan et al. (1996) found that nicotine reduced N200 latencies but increased N200 amplitudes (vs. placebo) in healthy subjects; a review by Pritchard, Sokhadze, and Houlihan (2004) also found that nicotine increased N200 amplitudes in healthy subjects.
A smaller number of studies have examined the effect of GABAergic agents on the P300 and N200 ERPs (and associated subcomponents). For instance, GABA A receptor agonists such as benzodiazepines have been shown to dampen auditory P3b amplitudes (Hayakawa et al., 1999) in healthy participants. Further, activation of GABA A receptors with thiopental has been reported to diminish attentional processing and reduce P3a/P3b and N2b amplitudes relative to placebo (Watson et al., 2009 ). Similar to nicotine, interindividual variability in GABA-enhancing drugs has been shown to be baselinedependent. Single dose administration of the GABA-mimetic sodium valproate in healthy subjects was found to increase P300 and N200 amplitudes in individuals with low baseline amplitudes, while decreasing P300 and N200 amplitudes in those with high baseline amplitudes (Urasaki, Ogura, Hirano, & Tomori, 1994) .
GABA signaling in the brain is mainly controlled by the enzyme glutamic acid decarboxylase (GAD), which accounts for the rate-limiting step in the synthesis of GABA from glutamate (Erlander, Tillakaratne, Feldblum, Patel, & Tobin, 1991) . The human nervous system contains two major isoforms of GAD, GAD67 and GAD65, which are encoded by the GAD1 and GAD2 genes, respectively (Bu et al., 1992) . GAD67
and GAD 65 synthesize~70% and~30% of the brain's GABA, respectively (Martin & Tobin, 2000; Soghomonian & Martin, 1998) . Moreover, several studies have shown that nicotine administration can enhance the release of several neurotransmitters, including GABA, by binding to nAChRs. A single exposure to nicotine has been shown to transiently increase GABA transmission, which can then lead to desensitization of nAChRs (Fagen, Mansvelder, Keath, & McGehee, 2003; Mansvelder, Keath, & McGehee, 2002) . Further evidence has demonstrated that activation of nAChRs located in GABA interneurons enhances inhibitory transmission (Hajos, 2005; Ji & Dani, 2000) and is implicated in the maturation of the GABA system (Liu, Neff, & Berg, 2006) . The findings from these studies suggest that nicotine modulates neuronal GABA transmission, which in turn may influence GABAergic-mediated cognitive domains.
Some single nucleotide polymorphisms (SNPs) in the GABAsynthesizing gene have been linked with cognitive performance. For instance, a study by Lett et al. (2016) found that GAD1 allelic variants (rs3749034) were related to worse performance on working memory tasks and on Stroop task reaction times in healthy volunteers and schizophrenic populations (who exhibit cognitive, including attentional, impairments), indicating that genotypic variation in GAD1 may influence executive functioning and working memory. Previous work has also shown that the GAD1 SNP (rs7557793) is strongly associated with a variety of cognitive domains including declarative memory, attention, and working memory in a sample that included siblings of patients with schizophrenia and healthy subjects (i.e., unrelated participants with no previous history of psychiatric disorders; Straub et al., 2007) . Neuroimaging results from the latter study, however, revealed that the rs7557793 SNP was linked with inefficient activation of the right dorsal PFC in healthy subjects. This particular T/C SNP is located in the 5′ flanking region of the GAD1 gene (chr 2, position 171 490 832; Marenco et al., 2010) , which is the noncoding part of the gene.
Few studies have investigated the effect of GAD1 SNPs on attention in healthy participants, as well as the interaction between GAD1 SNPs and the cholinergic system. Thus, the primary objective of this study was to examine the moderating role of the GAD1 (rs7557793) gene SNP on P300-indexed auditory attentional processing and the effects of acute nicotine administration on this ERP as a function of GAD1 genotype in healthy individuals. As a secondary objective, we examined GAD1 effects on the N200 response to nicotine. In order to rule out possible confounding effects of smoking withdrawal and menstrual cycle variations, the study was conducted in a sample of male nonsmokers.
| METHODS

| Participants
Right-handed, nonsmoking (<100 lifetime cigarettes) healthy male volunteers, aged 18-40 years (mean age = 23; SE ± 2.1), were recruited from the community using social media, online postings, and word-of- (First, Spitzer, Gibbon, & Williams, 1995) was administered to evaluate personal psychiatric history, whereas the Family Interview for Genetic Studies (Maxwell, 1992 ) assessed psychiatric histories in first-degree family members. The purpose, procedure, and potential risks/benefits of the study were outlined in the informed consent, and written consent was obtained from all participants. The
Research Ethics Board of the Royal Ottawa Health Care Group approved this study.
| Design
The data analyzed in this report were taken from a series of studies examining the effects of different acute psychotropic drug challenges, including nicotine, on the P300. A total of 126 participants were involved, all of whom received placebo in one session and a single dose of a psychotropic agent in another session, with a subsample of 59 receiving nicotine. Data from participants administered other drug challenges in their second session were not included in this study (i.e., only the nicotine subsample was included). Using a randomized double-blind crossover design, the effects of nicotine (vs. placebo)
were assessed whereby the subsample of participants attended two separate sessions, 1-5 days apart. Nicotine was administered in the first session to half of the randomly selected participants, placebo in the second session; the remaining half received treatments in the reverse order. Saliva samples were collected for genotype assessments in all participants (i.e., all 126 participants).
Test sessions occurred between 8:30 a.m. and 2:00 p.m. with participants abstaining overnight from smoking, drug and alcohol use, and from food 2 hr before arrival. Volunteers verbally confirmed their compliance with the abstinence instructions before being seated in a dimly lit chamber. Nicotine or placebo was administered to participants simultaneously with EEG electrode placement, followed by ERP data acquisition. For safety purposes, pre-and posttreatment vital signs were collected and adverse events were documented by having participants complete the Checklist of Nicotine Related Symptoms (adapted from Harkrider & Hedrick, 2005) .
| Nicotine
In line with previous studies (Knott, Millar, Fisher, & Albert, 2010 , 2013 , cinnamon-flavored Nicorette© gum (Johnson & Johnson, Inc.) was administered orally to participants in two separate pieces (4 mg + 2 mg). Previous pharmacokinetic studies have shown that a 6-mg dose of nicotine produces a similar blood nicotine level (Hukkanen, 2005) as smoking a single, average nicotine yield cigarette, equivalent to a blood nicotine concentration of~15-30 mg/ml.
Gum administration followed the manufacturer's guidelines, with the gum pieces being chewed for 25 min, biting twice every minute (cued by audio recordings), and being placed between the teeth and cheek between bites. With an elimination half-life of 120 min, blood nicotine levels have been shown to peak at~30 min after the commencement of chewing. Placebo cinnamon-flavored gum pieces were matched for size, color, texture, and taste. In order to reduce sensory differences between placebo and nicotine, participants were blindfolded and wore nose plugs for the entire length of the chewing period.
2.4 | Event-related potentials 2.4.1 | Stimuli
The auditory P3a/b was assessed using a modified auditory (threestimulus) oddball sequence, whereby participants were instructed to respond as quickly as possible (right index finger response on a mouse) to an infrequent low-pitched target tone (1,500 Hz, 60 ms, 80 dB) embedded among frequently occurring higher pitched standard tones 
| Recordings and processing
Similar to our previously published methods (Knott et al., 2014) Using BrainVision Recorder® software, the digital sampling rate was 500 Hz and electrode impedances were kept <5 kΩ. EEG recordings were carried out using a BrainVision V-Amp® (Brain Products, Gmbh, Munich, Germany; filters set at 0.1-100 Hz).
BrainVision Analyzer® (Brain Products, Gmbh, Munich, Germany)
software was used for analysis. The raw EEG were segmented (duration: 1,000 ms; starting at 100 ms prestimulus onset) into standard, target, and novelty epochs, and filtered at 0.1-30 Hz (Knott et al., 2014) . Ocular movements and blinks were corrected using the Gratton, Coles, and Donchin (1983) algorithm, and segments with EEG exceeding ±75 μV were removed from further analysis. Target, standard, and novelty segments were averaged separately and baseline corrected (100 ms prestimulus). Digital point-by-point subtraction of activity elicited by standard tones from activity elicited by target and novel stimuli yielded difference P3a (dP3a) and difference P3b
(dP3b) components. Based on the grand averaged difference waveforms, each participant's final dP3a (at Cz) and dP3b (at Pz) amplitudes were measured as the average voltage within five time points (10 ms)
to the left and right of the peak positivity detected within a 200-to 600-ms window, poststimulus onset (all amplitudes were measured relative to the mean prestimulus baseline). The amplitudes of the difference N2a (dN2a; to novel sounds) and N2b (dN2b; to target sounds) components were peak detected within the 200-to 350-ms time window at Fz.
| Genotyping
Each participant was genotyped for 12 SNPs located on eight genes:
CHRNA7 (rs904952 and rs3087454), SLC5A7 (rs1013940), CHRNA4
(rs1044396), ErbB4 (rs7598440, rs74650692, rs112073796, and rs6218545), NRG3 (rs10748842), NRG1 (rs783406), CNR1
(rs10591494), and GAD1 (rs7557793 
| Data analysis
The Statistical Package for Social Sciences (SPSS Version 23.0; SPSS Inc., Chicago, IL) was used to carry out data analysis on ERP and behavioral measures. With the ERP data collected in the total (N = 126) sample, separate one-way analysis of variance was used to assess the effects of genotype (three variants) on the dP3a (at Cz), dP3b (at Pz), dN2a (at Fz), and dN2b (at Fz) peak amplitudes and latencies. In the subsample (N = 59) receiving placebo and nicotine, separate mixed analyses of variance were used to assess the effects of GAD1 on nicotine response, with genotype acting as the between group factor while drug (placebo, nicotine) served as the within group factor. In the subsample, only ERP amplitude was assessed as no significant latency effects were noted in the full sample (outlined in Section 3). Significant effects (p < 0.05) were followed up with Bonferroni-adjusted post hoc comparisons. Any significant follow-up comparisons involving genotype focused on the comparisons between CT and TT, whereas comparisons with the CC genotype are descriptive (given the comparatively small CC sample size). A similar approach for dealing with unequal allelic frequency distributions in HW equilibrium has been used in previous studies examining genotype differences in relation to P300 ERPs (Kang, Xu, Liu, & Yang, 2010; Tsai et al., 2003) .
3 | RESULTS
| Genotype distribution
In the total sample (N = 126), N = 9 were CC, N = 32 were CT, and N = 85 were TT. In the subsample administered both placebo and nicotine (N = 59), the frequency of the genotypes was N = 6 CC, N = 15
CT, and N = 38 TT. No significant difference in age was observed existed between the three genotype groups.
3.2 | ERP data 3.2.1 | dP3a component GAD1 allelic variation failed to moderate dP3a amplitudes in the total sample ( Figure 1a ). In the subsample administered nicotine, there were no significant genotype, drug, or interaction effects (Figure 2) . No significant effects were observed for dP3a latency for the whole group (subsample not assessed).
| dN2a component
Neither amplitude nor latency of dN2a were affected by genotype in the total sample (Figure 1a ). In the subsample, a significant drug, F (1, 56) = 4.89, p < 0.05, and genotype effect, F (2, 56) = 4.03, p < 0.05, were observed for dN2a amplitudes (no significant interaction was 
| dP3b component
Analysis of dP3b amplitudes in the total sample ( Figure 1b 
| Behavioral data
No significant effects were observed for reaction time or response accuracy in either of the two samples.
| Adverse events
None of the participants receiving nicotine dropped out of the study or experienced any notable side effects.
FIGURE 2 Grand average difference N2a/P3a (dN2a/P3a; elicited by novel stimuli) and dN2b/P3b waveforms (elicited by target stimuli) in the subsample (N = 59) following placebo and nicotine administration in CC, CT, and TT genotypes. The dN2a ERP is included for illustration purposes at electrode site Pz (assessments were only carried out at Fz) FIGURE 3 Mean (±SE) difference N2a (dN2a) amplitude at electrode site Fz following nicotine and placebo administration in the CC, CT, and TT allele groups allelic variation moderated early sensory processes (N2a) in the subsample and influenced late cognitive processes (P3b), whereas nicotine (vs. placebo) had an effect only on earlier cognitive processes in the overall sample.
Given that a greater N2a amplitude is believed to reflect enhanced early sensory processing, CC/CT (i.e., "C" allele) carriers may be better at moderating early sensory processes compared with TT carriers. However, CC/CT carriers were shown to have smaller dP3b amplitudes (which is typically thought to reflect diminished late cognitive processes such as voluntary attention) as compared with TT carriers. It appears that this difference may be more pronounced between CC versus TT carriers; however, this is somewhat speculative because our CC sample was limited. Replication with a larger sample is certainly warranted.
P300 indices of novelty and target processing and N200 indices of early, pre-attentive processing have, to our knowledge, not been investigated in relation to GAD1 polymorphisms in healthy subjects.
However, two previous studies have shown that SNPs located in the 5′ region of the GAD1 gene, including the SNP analyzed in the current study (rs7557793), may, in part, moderate cognitive functions such as working memory and attention in healthy participants (Lett et al., 2016; Straub et al., 2007) . GAD1 SNPs in this region have also been linked with impaired cognitive functions in individuals with schizophrenia (Akbarian & Huang 2006) . Although the GAD1 SNP (rs3749034) was related to cognitive function in a previous study (Lett et al., 2016) , we only sequenced and analyzed the rs7557793 GAD1 SNP in the current study (i.e., rs3749034 was not sequenced/analyzed). Previous evidence suggests that the GAD1 SNPs rs7557793 and rs3749034 are nonrandomly associated with each other and in proximity (Marenco et al., 2010) , meaning that these SNPs should not be analyzed together.
Although CC homozygotes occur less frequently than the other genotypes, several studies investigating the association between SNPs (in the catechol-O-methyltransferase gene, for instance) and the P300 have used similar genotype frequency distributions as we did (Gallinat et al., 2003; Tsai et al., 2003) . In the current study, GAD1 genotype status revealed that TT homozygotes had greater P3b amplitudes than CC homozygotes in the overall (i.e., large) sample, suggesting that underlying processes in TT (vs. CC) homozygotes may be more optimal in selectively detecting infrequent auditory target tones (P3b) in sustained attention tasks. Previous studies have demonstrated that the P300 is, in part, generated by the release of GABA and requires an optimal level of excitatory-inhibitory balance in order to accurately index neural networks implicated in the allocation of attentional resources, context updating, and working memory (Luck et al., 2011) .
Specifically, prior investigations have shown that GABA activity affects P300 amplitude, possibly through glutamatergic modulation (Frodl-Bauch, Bottlender, & Hegerl, 1999; Kenemans & Kähkönen, 2010) . GABA functioning has been known to regulate a number of neural processes, including attention (Paine et al., 2011) and working memory (Auger & Floresco, 2014) , in healthy subjects. Modulations in GABA functioning have also been associated with cognitive deficits seen in psychiatric disorders such as schizophrenia, autism, and depression (Paine, Cooke, & Lowes, 2015) .
Despite being in HW equilibrium, genotype only affected dN2a amplitudes in the subsample. This may have occurred due to random subsampling of the total population, which inevitably produces different allele frequencies in HW equilibrium. In the subsample, we found that CT (vs. TT) GAD1 carriers exhibited increased N2a amplitudes, which may possibly implicate the GABA system in pre-attentive auditory processes underlying stimulus detection. A recent study by Cheng, Niddam, Hsu, Liu, and Tsai (2017) revealed an association between pre-attentive automatic, attentive inhibitory control, and GABA levels in the auditory system using a Go-NoGo task. Previous studies have also found that measures of pre-attentive auditory processing are strongly associated with higher order cognitive abilities and psychosocial functioning in healthy subjects (Light, Swerdlow, & Braff, 2007) and individuals with schizophrenia (Braff & Light, 2005) .
GABA may play a role in regulating the automatic detection of stimuli in the earlier stages of information processing, which in turn may facilitate later attention-dependent cognitive resources such as encoding, retrieval, and discrimination of task-relevant information.
Our findings demonstrated that nicotine (vs. placebo) had an effect on the N200 ERP, regardless of genotype. This suggests that nicotine-mediated cognitive enhancements (indexed by increased N2a/b amplitudes) may occur by improving pre-attentive processing of sensory stimulus changes and stimulus classification processes. Furthermore, our results are consistent with previous work examining nicotine's effect on pre-attentive processes, which have been commonly FIGURE 5 Mean (±SE) difference N2b (dN2b) amplitude at electrode site Fz following nicotine and placebo administration in CC, CT, and TT allele groups studied with the mismatch negativity (MMN) ERP. This particular neurophysiological marker indexes N2a-related processes during passive paradigms requiring no attentional or behavioral response (Näätänen, Paavilainen, Rinne, & Alho, 2007) . In intermodal (visual and auditory) selective and divided attention tasks, N200 component amplitudes were increased in acute smokers (Knott et al., 2009) , irrespective of the attentional condition, and therefore nicotine's enhancing effect on N200 s may reflect sensory change detection processes that occur in a relatively attention-independent manner (Kujala et al., 2007; Näätänen et al., 2007) . As indexed by the MMN, nicotine has been shown to enhance auditory (Harkrider & Hedrick, 2005; Inami, Kirino, Inoue, & Arai, 2005; Baldeweg, Wong, & Stephan, 2006; Knott et al., 2006; Martin, Davalos, & Kisley, 2009 ) and visual sensory detection of physical deviants in healthy participants, whereas selective nAChR agonists enhanced the auditory MMN in healthy males (Dunbar et al., 2007) . Individual differences in the N2a response to nicotine (Knott et al., 2014) , and α7-nAChR agonists (Knott et al., 2015) have also been reported with the deviant-elicited MMN, as individuals with minimal deviance detection (smaller MMNs) tend to exhibit greater amplitude increases than those with optimal (larger MMNs) detection ability.
Although no regulatory functions have been found to be associated with this particular SNP (rs7557793), the 5′ flanking region of the GAD1 gene has been extensively genotyped in patients with schizophrenia and healthy subjects, given that it plays a major role in regulating the gene's expression (Addington et al., 2005; Du et al., 2008; Marenco et al., 2010) . There is also evidence from Straub et al. (2007) showing an association between the rs7557793 SNP and frontal brain activity in the context of working memory in healthy subjects. Furthermore, Addington et al. (2005) found that rs7557793 was significantly associated with increased frontal lobe gray matter volume in individuals with childhood-onset schizophrenia, possibly implicating this particular SNP in abnormalities associated with frontally controlled executive function processes (i.e., attention and cognitive control). However, further studies are needed to investigate the functionality of the rs7557793 GAD1 SNP in healthy subjects.
| LIMITATIONS
Several methodological limitations exist in the current study. The subsample size was relatively small and restricted to healthy young male nonsmokers; as such, our statistical power and generalizability are limited. Further, only one SNP for the GAD1 gene was examined and thus provides a limited interpretation of GABAergic genotypic influences on ERPs such as the P300. The current study did not conduct a statistical procedure to correct for multiple comparisons among the 12 SNPs genotyped; this should be considered when interpreting the significance of the results. Because acute and chronic smoking differentially affect the nACh system, acute doses of nicotine used in this study would be difficult to extrapolate to populations who use nicotine chronically (e.g., chronic smokers). Further, nicotine blood levels were not measured post drug administration, thus, important pharmacokinetic factors (e.g., concentration) could not be assessed.
Finally, P3a was measured only via its amplitude and latency; improving the measurement of this ERP by extracting EEG power estimates in specific frequency bands of the P300 and/or by examining singletrial variability have been suggested as approaches for mapping this endophenotype onto a separate SNP or genes (Ford, 2014 were found with nicotine versus placebo, regardless of genotype. To our knowledge, this is the first study to examine the combined influence of nicotine administration and GAD1 genotype status on both N200-and P300-indices of attentional processing. These findings may inform targeted pharmacogenetic-based therapies for alleviating attentional impairments in disorders such as schizophrenia, as well as to direct future studies on the genotypic influence of GABAergic mechanisms on implicated cognitive domains such as attention and working memory.
